Treating advanced melanoma: current insights and opportunities
Open Access
- 1 September 2014
- journal article
- review article
- Published by Informa UK Limited in Cancer Management and Research
- Vol. 6, 349-56
- https://doi.org/10.2147/CMAR.S49494
Abstract
Treating advanced melanoma: current insights and opportunities Michael Tronnier, Christina Mitteldorf Department of Dermatology, Klinikum Hildesheim GmbH, Hildesheim, Germany Whereas thin melanomas have an excellent prognosis after sufficient surgical treatment, melanoma disease in advanced stages is still a therapeutic challenge. After decades of frustrating studies, new therapeutic strategies have come up in the past few years. On the one hand, increasing insights into the molecular aberrations in melanoma have led to specific "targeted" therapies to affect only the mutated tumor cells, as in many other types of cancers. Today there are few "targeted" substances which are already approved and successfully used for single or combination therapy, but many others are under development. While on the other hand, nonpersonalized strategy substances have been developed successfully inducing an immunologic tumor response. Both kinds of therapy have been found to result in an improvement not only of the response rate, but also of the overall survival in metastatic disease, which represents a milestone in melanoma therapy. However, using these therapies there is still much to learn regarding the effects, the side effects, and the limitations of these promising substances. Keywords: melanoma, treatment, targeted therapy, immunotherapy, BRAF, CTLA-4Keywords
This publication has 57 references indexed in Scilit:
- Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanomaCancer Gene Therapy, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- Increasing Burden of Melanoma in the United StatesJournal of Investigative Dermatology, 2009
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysisBritish Journal of Cancer, 2006